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CYP1B1 has been evaluated as a candidate gene for various cancers because of its function in activating environmental procarcinogens
and catalysing the conversion of oestrogens to genotoxic catechol oestrogens. To test the hypothesis that genetic polymorphisms in
the CYP1B1 gene may associate with the risk for prostate cancer (CaP), we compared the allele, genotype, and haplotype frequencies
of 13 single nucleotide polymorphisms (SNPs) of CYP1B1 among 159 hereditary prostate cancer (HPC) probands, 245 sporadic CaP
cases, and 222 unaffected men. When each of the SNPs was analysed separately, marginally significant differences were observed for
allele frequencies between sporadic cases and controls for three consecutive SNPs ( 1001C/T,  263G/A, and  13C/T, P¼0.04–
0.07). Similarly, marginally significant differences between sporadic cases and controls in the frequency of variant allele carriers were
observed for five consecutive SNPs ( 1001C/T,  263G/A,  13C/T, þ142C/G, and þ355G/T, P¼0.02–0.08). Interestingly,
when the combination of these five SNPs was analysed using a haplotype approach, a larger difference was found (P¼0.009). One
frequent haplotype (C-G-C-C-G of  1001C/T,  263G/A,  13C/T, þ142C/G, and þ355G/T) was associated with an increased
risk for CaP, while the other frequent haplotype (T-A-T-G-T) was associated with a decreased risk for CaP. These findings suggest
that genetic polymorphisms in CYP1B1 may modify the risk for CaP.
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The CYP1B1 gene encodes an extrahepatic cytochrome P450
enzyme that activates many structurally diverse environmental
procarcinogens, including polycyclic aromatic hydrocarbons
(PAHs), heterocyclic and aryl amines, and nitroaromatic hydro-
carbons (Shimada et al, 1996; Kim et al, 1998). When activated,
these procarcinogens produce reactive intermediates that can
cause DNA damage in cells. The importance of CYP1B1 in
chemical carcinogenesis has been demonstrated in a knockout
mouse model (Buters et al, 1999; Heidel et al, 2000). Although
CYP1B1-null mice were found to be resistant to 7,12-DMBA,
among wild-type counterparts this known procarcinogen induced
malignant lymphoma, as well as bone marrow cytotoxicity and
preleukaemia. In addition to its role in procarcinogen activation,
CYP1B1 is also involved in the oxidative metabolism of oestrogens,
as it preferentially catalyses the hydroxylation of oestrogens at the
C-4 position to 4-hydroxy CEs (Hayes et al, 1996). 4-hydroxy CEs
can form depurinated DNA adducts and was found to be
carcinogenic in several animal models (Yager and Liehr, 1996).
Owing to its role in the metabolism of both environmental and
endogenous procarcinogens, CYP1B1 is hypothesised to play an
important role in carcinogenesis.
The human CYP1B1 gene has been mapped to chromosomal
region 2p21–22 (Sutter et al, 1994). CYP1B1 consists of three
exons, with the coding region starting in exon 2 (Tang et al, 1996).
Many single nucleotide polymorphisms (SNPs) in the CYP1B1
gene have been reported (http://www.ncbi.nlm.nih.gov/SNP/
snp_ref.cgi?locusId¼1545), of which four cause amino-acid
substitutions (SNP C142G, G355T, C4326G, and A4390G, which
result in Arg48Gly (R48G), Ala119Ser (A119S), Leu432Val (L432V),
and Asn453Ser (N453S) amino-acid substitutions, respectively).
The R48G substitution is located only two amino acids upstream of
a highly conserved PPGP region, which is important for proper
protein folding and stability (Nelson and Strobel, 1988; Johansson
et al, 1994). The A119S substitution is located in substrate
recognition site one (SRS1) (Gotoh, 1992), and may affect substrate
binding. The other two nonsynonymous changes, L432V and
N453S, are both located in exon 3, which encodes the haem-
binding domain. Multiple functional studies report that these
nonsynonymous SNPs of CYP1B1 alter enzymatic activity and
catalytic specificity. However, the results have not been consistent
and are difficult to compare because different variants were tested
(a total of 16 combinations for four amino-acid substitutions), and
different expression and assay systems were used, in each
laboratory (Hanna et al, 2000; Li et al, 2000; McLellan et al,
2000; Shimada et al, 2001; Aklillu et al, 2002).
The association between the polymorphisms of CYP1B1,
especially L432V, and susceptibility to several cancers has been
investigated. This includes smoking-related head and neck
squamous cell cancer, colorectal, breast, ovarian, and prostate
cancers (Bailey et al, 1998; Fritsche et al, 1999; Goodman et al,
2001; Ko et al, 2001; De Vivo et al, 2002; Tanaka et al, 2002; Tang
et al, 2000; Watanabe et al, 2000; Zheng et al, 2000). However, few Received 27 March 2003; revised 13 July 2003; accepted 25 July 2003
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SNPs in CYP1B1 and cancer risk. Considering that sequence
variants in the noncoding region may also affect the regulation and
function of genes and the difficulty of functional characterisation
of various CYP1B1 isoforms in vitro, analysing multiple SNPs
simultaneously may provide more direct evidence for the relation-
ship between cancer risk and the genetic polymorphisms in
CYP1B1. Based on the function of CYP1B1 in activating
procarcinogens and transforming oestrogens to genotoxic 4-
hydroxyl-CEs, we hypothesise that polymorphisms in CYP1B1
may affect the risk for prostate cancer. In addition, we hypothesise
that polymorphisms in CYP1B1 impose a different risk for
hereditary prostate cancer compared to sporadic prostate cancer.
To test these hypotheses, we estimated the frequencies and tested
for differences in the frequencies of CYP1B1 SNPs among 159 HPC
probands, 245 sporadic prostate cancer cases, and 211 unaffected
men.
MATERIALS AND METHODS
Subjects
HPC families (n¼159) were recruited at the Brady Urology
Institute at Johns Hopkins Hospital (Baltimore, MD, USA),
through referrals, review of medical records for patients seen at
Johns Hopkins Hospital for treatment of prostate cancer, and
respondents to various lay publications describing our studies. The
eligibility criterion for HPC was at least three first-degree relatives
affected with prostate cancer. The diagnosis of CaP was verified by
medical records for each affected male studied. The age of
diagnosis of CaP was confirmed either through medical records or
from two other independent sources. The mean age at diagnosis
was 61 years; 134 (84%) were Caucasian and 14 (8.8%) were
African American. The average number of affected men per family
was 5.08.
Sporadic CaP cases (n¼245) were from patients who underwent
treatment for CaP at the John Hopkins Hospital and agreed to
participate in the prostate cancer genetic study. Patients who met
the criterion for HPC were excluded from this group. The
diagnosis of CaP for all these subjects was confirmed by pathology
reports. The mean age at diagnosis for these cases was 58.7 years;
229 (93%) were Caucasian and 8 (3.3%) were African American.
Non-CaP controls (n¼222) were selected from men participat-
ing in screening programmes for CaP. By excluding subjects with
abnormal PSA levels (i.e., X4ngml
 1), 217 were eligible for the
study. The mean age at examination was 58 years; 188 (86.6%) of
the eligible controls were Caucasian and 15 (6.9%) were African
American. Based on interviews with the controls, about 5.5% of the
eligible controls had brothers or a father affected with CaP.
All individuals who participated in this study gave full informed
consent.
Genotyping and statistical methods
In all, 20 SNPs distributed throughout the CYP1B1 gene, including
the promoter region, all exons, and all introns, were selected
from Entrez dbSNP (http://www.ncbi. nlm.nih.gov/SNP/snp_ref.cgi?
locusId¼1545) and were then genotyped in 24 unrelated Cauca-
sians to estimate the frequency, using the MassARRAY system
(SEQUENOM Inc., San Diego, CA, USA) according to the
manufacturer’s recommendation. Among these 20 SNPs, we
performed additional genotyping for 13 SNPs that were informative
and frequent (frequency 45%) among all HPC probands, sporadic
prostate cancer cases, andunaffected controls. AsdetailedinTable1,
this sub-sample of 13 SNPs included two SNPs in the promoter
region, four nonsynonymous and one synonymous SNPs in the
coding region, two SNPs in intron1, 1 SNP in intron 2, and two SNPs
in the 50UTR region.
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for each sequence variant and a pairwise linkage disequilibrium
(LD) test for all sequence variants using the Fisher probability test
statistic, as described by Weir (1996). For each test, 10000
permutations were performed and the test statistic of each
replicate was calculated. Empirical P-values for each test were
estimated as the proportion of replicates that is as probable or less
probable than the observed data, as implemented in the software
package Genetic Data Analysis (GDA).
Tests for SNP allele frequency differences between cases and
controls were performed using the w
2 with a degree of freedom of
1. An unconditional logistic regression was used to test for an
association between genotypes and prostate cancer, after combin-
ing two types of variant allele carriers (heterozygotes or
homozygotes) into one group and adjusting for age.
The haplotype frequency of unrelated individuals was estimated
using the new statistical method proposed by Stephens et al (2001),
as implemented in the computer program PHASE (http://
www.stats.ox.ac.uk/mathgen/software.html). Several runs using
different values for the seed of the random number generator
were performed and the goodness-of-fit values were similar among
the different runs. An association between the haplotypes and
prostate cancer risk was obtained using a score test developed by
Schaid et al (2002), as implemented in the computer program
HAPLO.SCORE (http://www.mayo.edu/statgen for the S-PLUS
programming language or http://www.wfubmc.edu/docs/genomics
for the R programming language).
RESULTS
Since over 90% of the study subjects were Caucasians, all analyses
were limited to Caucasians only, to decrease the potential for
population stratification. All the SNPs were in HWE (P40.05) in
each subset and were in strong LD, with the estimates of pairwise
correlation coefficients ranging from 0.22 to 1.00 (Table 1). When
each SNP was evaluated individually, marginally significant
differences of allele frequencies between sporadic cases and
controls were observed for three consecutive SNPs ( 1001C/T,
 263G/A, and  13C/T) (Table 2). Similarly, marginally significant
differences of genotype frequencies between sporadic cases and
controls were found for five consecutive SNPs ( 1001C/T,  263G/
A,  13C/T, þ142C/G, and þ355G/T (Table 3). For example,
compared with the unaffected men (52.46%), the frequency of ‘T’
allele carriers of the SNP  13C/T was significantly lower in
sporadic cases (41.23%, P¼0.02). As these five SNPs were in
strong LD (pairwise correlation coefficient ranging from 0.99 to
1.0), it is difficult to examine whether these observed associations
were independent or an outcome of LD with a causal SNP.
Interestingly, when the combination of these five SNPs was
analysed using haplotype approaches, the haplotype frequencies
were significantly different between sporadic cases and controls
(Table 4). Within the eight observed haplotypes, only two
haplotypes, C-G-C-C-G and T-A-T-G-T (for SNPs  1001C/T,
 263G/A,  13C/T, þ142C/G, and þ355G/T), were common. The
remaining six haplotypes were observed less than 0.5% among our
study population and were therefore excluded in the later analyses.
A global haplo score test provided a significant difference between
sporadic cases and controls, with a P-value of 0.009 (Table 4). The
haplotype C-G-C-C-G was associated with increased risk for CaP,
with a frequency of 73% in sporadic cases and 68% in controls.
The other haplotype T-A-T-G-T was associated with a decreased
risk for CaP, with a frequency of 24% in sporadic cases and 31% in
controls. However, no significant difference was observed for
allele, genotype, and haplotype frequencies between HPC probands
and controls (Tables 2–4).
Since most functional studies have evaluated the impact of four
nonsynonymous changes on CYP1B1 enzymatic activity, we also
compared the haplotype frequencies of these four nonsynonymous
changes: þ142C/G (R48G), þ355G/T (A119L), þ4326C/G
(L432V), and þ4390A/G (N453S) between the cases and controls.
Ten out of 16 possible haplotypes were observed in our study
subjects. However, except for haplotypes G-T-C-A, C-G-G-A, C-G-
C-A, and C-G-C-G, the rest of the haplotypes were rare (o0.5%)
and not included in later analyses. Again, a significant difference
between sporadic cases and controls was observed in a global
haplo score test, with a P-value of 0.02 (Table 4). When specific
haplotypes were examined, haplotype G-T-C-A was associated with
a decreased risk for CaP, with the frequency of 24% in sporadic
cases and 31% in controls. The frequencies of the remaining
haplotypes were very similar between sporadic cases and controls.
There was no significant difference in the haplotype frequency
between HPC probands and controls.
DISCUSSION
In this study, we tested for an association between polymorphisms
in the CYP1B1gene and prostate cancer risk by comparing the
allele, genotype, and haplotype frequencies of CYP1B1 SNPs
Table 2 Allele frequencies of CYP1B1 polymorphisms
Controls Sporadics HPC probands
SNP
a Location
Variant
allele
No. of chromosomes
with variant
(no. of total chromosomes)
No. of chromosomes
with variant
(no. of total chromosomes)
P-value
b No. of chromosomes
with variant
(no. of total chromosomes)
P-value
c
 1549A/G Promoter G 70 (350) 98 (438) 0.42 46 (240) 0.9
 1001C/T Promoter T 109 (352) 110 (440) 0.07 71 (240) 0.63
 263G/A Intron 1 A 112 (366) 111 (456) 0.05 74 (244) 0.87
 13C/T Intron 1 T 112 (366) 113 (454) 0.07 71 (242) 0.66
+142C/G (R48G) Exon 2 G 114 (368) 116 (452) 0.1 70 (238) 0.6
+355G/T (A119S) Exon 2 T 115 (370) 121 (454) 0.16 74 (244) 0.77
+3653C/A Intron 2 A 68 (366) 73 (446) 0.39 33 (232) 0.16
+4326C/G (L432V) Exon 3 G 160 (364) 187 (414) 0.72 76 (206) 0.1
+4379C/T (D449D) Exon 3 T 166 (370) 193 (424) 0.84 86 (226) 0.12
+4390A/G (N453S) Exon 3 G 56 (364) 78 (404) 0.16 43 (224) 0.23
+5359T/G 30UTR G 74 (346) 87 (402) 0.92 48 (258) 0.34
+5639G/A 30UTR A 154 (346) 193 (428) 0.86 88 (236) 0.09
+7072A/T 30UTR T 77 (360) 107 (452) 0.42 48 (238) 0.88
aNumeric values represent the position (in base pairs) from the transcription start site. The letter represents nucleotide change. The letter and number in each parenthesis
represent the amino acid change and the position of the amino-acid change.
bP-values of w
2 test for allele frequencies with df¼1.
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unaffected men. Although no significant difference in the
distributions of these SNPs between HPC probands and unaffected
controls was found, differences in allele and genotype frequency
between sporadic cases and controls were observed for several
consecutive SNPs. Furthermore, haplotype analysis revealed larger
differences between sporadic cases and unaffected controls and the
diversity of haplotypes was limited in Caucasians. The haplotype
C-G-C-C-G (for consecutive SNPs  1001C/T,  263G/A,  13C/T,
þ142C/G, and þ355G/T) was found to be associated with an
increased risk for sporadic prostate cancer, while the haplotype T-
A-T-G-T was associated with a decreased risk for sporadic prostate
cancer. Although the results cannot differentiate the contribution
of specific SNPs to the observed association, they suggest that a
specific segment of the gene is associated with prostate cancer risk.
This is the first study that systematically evaluates the influence of
multiple genetic variants in the CYP1B1 gene on prostate cancer
risk using a haplotype approach. It is also the first report to
include hereditary prostate cancer patients, which enabled us to
test whether the degree of association between the polymorphisms
of CYP1B1 and prostate cancer risk is strong enough to contribute
to familial aggregation of prostate cancer.
Caution should be exercised when interpreting our findings.
While the significant differences seen in the genotype and
haplotype frequencies between prostate cancer cases and controls
could be due to differential risks for prostate cancer caused by
these polymorphisms, it could also be due to other reasons, such as
a type I error or population stratification. All the reported
significance levels were nominal P-values, and were not adjusted
for multiple comparisons. When considering the fact that as many
as 13 SNPs were tested in this report (for prostate cancer risk), if
we use the commonly suggested Bonferoni correction, the results
are not significant. However, the Bonferoni correction is not
optimal in this case because not all of these tests were independent,
due to LD between these polymorphisms and the dependence
between allele, genotype, and haplotype. As a case–control study,
Table 3 Genotype frequencies of CYP1B1 polymorphisms
Controls Sporadics HPC probands
SNP Genotypes No. of subjects No. of subjects P-value
a No. of subjects P-value
b
 1549A/G AA 115 130 77
AG&GG 60 89 0.2 43 0.78
 1001C/T CC 83 127 61
TC&TT 93 93 0.04 59 0.54
 263G/A GG 87 132 62
AG&AA 96 95 0.03 59 0.53
 13C/T CC 87 134 61
TC&TT 96 94 0.02 61 0.67
+142C/G (R48G) CC 86 129 61
CG&GG 98 97 0.04 58 0.44
+355G/T (A119S) GG 86 125 61
GT&TT 99 102 0.08 61 0.55
+3653C/A CC 117 156 84
CA&AA 66 67 0.2 32 0.13
+4326C/G (L432V) CC 53 55 39
CG&GG 129 152 0.58 64 0.13
+4379C/T (D449D) CC 53 57 42
CT&TT 132 155 0.7 71 0.13
+4390A/G (N453S) AA 132 131 72
AG&GG 50 71 0.11 40 0.14
+5359T/G TT 102 124 84
TG&GG 71 77 0.59 45 0.28
+5639G/A GG 50 58 45
GA&AA 123 156 0.7 73 0.1
+7072A/T AA 112 127 74
AT&TT 68 99 0.22 45 0.99
aP- values of logistic regression adjusted for age.
bNS¼not significant.
Table 4 CYP1B1 haplotype frequencies
Frequencies Score test (P-values)
Haplotype Controls HPC Sporadic HPC vs controls Sporadic vs controls
( 1001C/T)-( 263G/A)-( 13C/T)-(+142C/G)-(+355G/T)
C-G-C-C-G 0.683 0.68 0.731 0.39 (0.69) 1.05 (0.29)
T-A-T-G-T 0.312 0.316 0.242  0.42 (0.67)  1.9 (0.057)
Global 0.23 (0.845) 9.69 (0.009)
(+142C/G)-(+355G/T)- (+4326C/G)-(+4390A/G)
G-T-C-A 0.31 0.32 0.24  0.01 (0.93)  1.75 (0.071)
C-G-G-A 0.44 0.38 0.43  1.80 (0.07)  0.24 (0.812)
C-G-C-A 0.09 0.13 0.13 1.17 (0.264) 0.52 (0.621)
C-G-C-G 0.15 0.17 0.16 1.34 (0.202) 0.17 (0.285)
Global 5.26 (0.263) 11.00 (0.02)
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the different genotype frequencies observed may partially reflect
different genetic backgrounds in cases and controls. However, we
feel that population stratification is unlikely to be substantial in
this population because: (1) the statistical tests were limited to
Caucasian subjects only, and (2) we observed no evidence for a
significant difference in the genetic background between cases and
controls, based on a sample of 24 consecutive SNPs recently
genotyped on chromosomes 1, 8, 11, 12, and X (data not shown).
Two possible interpretations can be made for the observed
larger difference between sporadic cases and unaffected men from
the haplotype analysis. Firstly, the different haplotype frequencies
may suggest a founder effect, that is, a substantial proportion of
cases inherited the chromosomal segment at CYP1B1 from a
common ancestor. Secondly, because each of these variants could
affect the function of CYP1B1, the specific combination of the
variants on the same chromosome (in cis position) may have a
particular phenotypic effect. Several laboratories have reported
functional studies on the effects of CYP1B1 polymorphisms on
procarcinogens and oestrogen hydroxylation activities. Different
allelic variants of CYP1B1 have different catalytic activities and
specificities to a variety of procarcinogens (Shimada et al, 2001).
No specific allelic variants showed higher activities for every
procarcinogen tested. In addition, due to different variant tests
reported in each paper (a total of 16 combinations for four amino-
acid substitutions) and different expression and assay systems
used between different laboratories, the results were not consistent
and were difficult to compare (Hanna et al, 2000; Li et al, 2000;
McLellan et al, 2000; Shimada et al, 2001; Aklillu et al, 2002). It is
difficult to draw conclusions from these previously reported
studies and even more difficult to predict the impact of these
variants on the risk of prostate cancer. In addition, the association
between haplotypes and prostate cancer risk observed in our study
also included polymorphisms in the intronic region immediately
preceding exon 1 ( 1001C/T,  263G/A,  13C/T). These intronic
polymorphisms, either individually or in combination, may affect
gene expression or mRNA splicing efficiency (Herrington et al,
2002). Further studies are needed to confirm these findings and to
examine the mechanisms.
The studies between genetic polymorphisms in the CYP1B1 gene
and risk to a variety of cancers have focused on amino acid
substitutions in exon 3, namely L432V and N453S. An association
has been reported for the L432V polymorphism and risk for
ovarian cancer (Goodman et al, 2001) and smoking-related head
and neck squamous cell cancer (Ko et al, 2001). For breast cancer,
while two studies (Bailey et al, 1998; De Vivo et al, 2002) failed to
detect an association between L432V polymorphism and breast
cancer risk in the Caucasian population, Zheng et al (2000)
reported that the V allele of L432V increased breast cancer risk in
Chinese women. Recently, Tanaka et al (2002) reported an
association study between CYP1B1 polymorphisms and prostate
cancer risk in a Japanese population that included 117 prostate
cancer cases and 200 controls. They found an opposite trend in
terms of association of the risk allele with prostate cancer. Within
four nonsynonymous SNPs and an SNP in intron 1 ( 13C/T) that
they examined, only SNP þ355G/T (A119S) was statistically
different between cases and controls, with the T allele being the
risk allele (32% in cases compared to 15% in controls). However,
we did not observe significant differences between cases and
controls when we analysed SNP þ355G/T (A119S) individually (T
allele frequency: 27% in sporadic cases, 31% in controls, and 30%
in HPC probands). The discrepancy between our results and their
studies may be due to different risks in different ethnic
populations. However, the deviation from HWE in their control
group makes their results difficult to interpret. Although there was
no association between SNPs in exon 3 and prostate cancer risk in
our study population, we observed an association between SNPs
near or within exon 1. It would be interesting to use other study
populations to test the association between prostate cancer risk
and several SNPs implicated by our study, including  1001C/T,
 263G/A,  13C/T, þ142C/G (R48G), and þ355G/T (A119S).
This is particularly true for the haplotypes of these SNPs.
No association between SNPs in the CYP1B1 gene and the risk to
hereditary prostate cancer was observed in this study, even though
our study provided preliminary evidence for an association
between CYP1B1 and sporadic prostate cancer risk. This result
indicates that either CYP1B1 gene has no effect, or only plays a
very minor role in familial aggregation of CaP. In fact, the power to
detect a risk genotype in our hereditary prostate cancer population
is limited when the genotype confers a low risk. For example, the
power to detect a risk genotype that confers a relative risk of 1.8 to
hereditary prostate cancer is only 70%, when the risk genotype is
present in 50% of the control population. In addition, it is very
likely that major susceptibility genes have a stronger effect in the
hereditary families, which could mask the influence of minor
genes.
In this study, we comprehensively studied the genetic variants of
CYP1B1 and the risk to prostate cancer, providing preliminary
evidence for an association between CYP1B1 haplotype and the
risk to prostate cancer. Further studies with a larger sample size
are needed to confirm our results.
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